Tubulo-interstitial fibrosis: An emerging major health problem;La fibrose tubulointerstitielle rénale Menace fantôme ou dernière croisade?

Medecine/Sciences

Volumn 27, Issue 1, 2011, Pages 55-61

  Klein, Julie ^a,b   Miravete, Mathieu ^a,b   Buffin Meyer, Bénédicte ^a,b   Schanstra, Joost P ^a,b   Bascands, Jean Loup ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

ANGIOTENSIN RECEPTOR ANTAGONIST; CHEMOKINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID; SIGNAL PEPTIDE;

ANIMAL; BIOLOGICAL MODEL; CELL HYPOXIA; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; INCIDENCE; INTERSTITIAL NEPHRITIS; KALLIKREIN KININ SYSTEM; KIDNEY; MACROPHAGE; METABOLISM; MORBIDITY; MOUSE; MYOBLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CELL HYPOXIA; CHEMOKINES; CYTOKINES; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; INCIDENCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KALLIKREIN-KININ SYSTEM; KIDNEY; KIDNEY FAILURE, CHRONIC; LYSOPHOSPHOLIPIDS; MACROPHAGES; MICE; MODELS, BIOLOGICAL; MORBIDITY; MYOBLASTS; NEPHRITIS, INTERSTITIAL; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM;

EID: 79951888746     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/201127155     Document Type: Review

References (42)

1. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988 ; 318:1657-66.
2. Nach KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20:1-17.
3. Meguid El Nafias A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005 ; 365:331-40. (Pubitemid 40139112)
4. Sean Eardley K, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int 2005 ; 68:437-55. (Pubitemid 43323099)
5. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005 ; 12: 353-65. (Pubitemid 41376493)
6. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest 2008 ; 118:3522-30.
7. Wang Y, Wang YP, Zheng G, et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007 ; 72: 290-9. (Pubitemid 47172367)
8. Velazquez P, Dustin ML, Nelson PJ. Renal dendritic cells: an update. Nephron Exp Nephrol 2009 ; 111:e47-71.
9. Heymann F, Meyer-Schwesinger C, Hamilton-Williams EE, et al. Kidney dendritic cell activation is required far progression of renal disease in a mouse model of glomerular injury. J Clin Invest 2009 ; 119:1286-97.
10. Holdsworth SR, Summers SA. Role of mast cells in progressive renal diseases J Am Soc Nephrol 2008 ; 19:2254-61.
11. Grande MT, Lopez-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 2009 ; 5: 319-28.
12. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy Am J Physiol Renal Physiol 2008 ; 294 : F697-701.
13. Giunti S, Tesch GH, Pinach S, et al. Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 2008 ; 51:198-207. (Pubitemid 350197986)
14. Eitner F, Bucher E, van Roeyen C, et al. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 2008 ; 19: 281-9. (Pubitemid 351240650)
15. Strutz F, Zeisberg M, Ziyadeh FN, et al. Role of basic fibroblast growth factor-2 in epithelialmesenchymal transformation. Kidney Int 2002 ; 61:1714-28. (Pubitemid 34437925)
16. Lautrette A, Li S, Alili R, et at. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005 ; 11: 867-74. (Pubitemid 41161119)
17. Liu Y, yang J. Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? Kidney Int 2006; 70: 238-40. (Pubitemid 44086571)
18. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 2004 ; 287 : F7-16.
19. Schievenbusch S, Strack I, Scheffler M, et al. Profiling of anti-fibrotic signaling by hepatocyte growth factor in renal fibroblasts. Biochem Biophys Res Commun 2009 ; 385: 55-61.
20. Giannopoulou M, Dai C, Tan X, et al. Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling. Am J Pathol 2008 ; 173: 30-41. (Pubitemid 351947953)
21. ZeisbergM, Hanoi J, Sugimoto H, et al. BMP-7 counteracts TGF-betal-induced epithelial-tomesenchymal transition and reverses chronic renal injury. Nat Med 2003 ; 9: 964-8. (Pubitemid 36889942)
22. Zeisberg M, Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 2008; 23:1395-8.
23. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006 ; 17: 2985-91. (Pubitemid 44707758)
24. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008 ; 214:199-210. (Pubitemid 351160157)
25. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-8.
26. Carvajal G, Rodriguez-Vita J, Rodrigues-Diez R, et al. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 2008;74:585-95.
27. Bascands JL, Schanstra JP, Couture R, et al. Les récepteurs de la bradykinme : de nouveaux rôles physiopathologiques. Med Sci (Paris) 2003 ; 19:1093-100. (Pubitemid 37432473)
28. Schanstra JP, Neau E, Drogoz P, et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002 ; 110: 371-9. (Pubitemid 34847969)
29. Klein J, Gonzalez J, Decramer S, et al. Blockade of the kinin B1 receptor ameloriates glomerulonephritis. J Am Soc Nephrol 2010 ; 21:1157-64.
30. Klein J, Gonzalez J, Duchene J, et al. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy, FASEB J 2009;23:134-42.
31. Pradere JP, Gonzalez J, Klein J, et al. Lysophosphatidic acid and renal fibrosis. Biochim Biophys Acta 2008 ; 1781: 582-7.
32. Prodere JP, Klein J, Gres S, et at. LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 2007 ; 18: 3110-8. (Pubitemid 350223970)
33. Hirschberg R, Wang S. Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease. Curr Opin Nephrol Hypertens 2005 ; 14:43-52. (Pubitemid 40110699)
34. Strutz FM. EMT and proteinuria as progression factors. Kidney Int 2009 ; 75:475-81.
35. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008 ; 74:867-72.
36. Higgins DF, Kimura K, Iwano M, et al. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle 2008 ; 7:1128-32. (Pubitemid 351749261)
37. Fioretto P, Sutherland DE, Najarian B, et al. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2004 ; 69: 907-12.
38. Chatziantoniou C, Dussaule JC. Is kidney injury a reversible process? Curr Opin Nephrol Hypertens 2008 ; 17: 76-81. (Pubitemid 350295201)
39. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998 ; 339: 69-75. (Pubitemid 28304880)
40. Ronco P, Chatziantoniou C. Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. Kidney Int 2008;74:873-8.
41. Servais A, Meas-yedid V, Morelon E, et al. Apports récents des techniques de quantification de la fibrose pour l'examen anatomo-pathologique en transplantation rénale. Med Sci (Paris) 2009 ; 25: 945-50.
42. Flamant M, Dussaule JC, Ardaillou R. Les effets profibrosants des peptides vasoactifs dans le rein et les vaisseaux passent-ils par la transactivation du facteur de croissance épidermique (EGF)? Med Sci (Paris) 2005 ; 21:461-3. (Pubitemid 40694794)